DALLAS, Sept. 15, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring biotechnology company StemCells Inc. (Nasdaq:STEM). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.

The investment report on StemCells Inc. (Nasdaq:STEM) should be of particular interest to other biotechnology companies: Geron Corp. (Nasdaq:GERN), Advanced Cell Technology Inc. (Pink Sheets:ACTC), Osiris Therapeutics Inc. (Nasdaq:OSIR) and Aastrom Biosciences Inc. (Nasdaq:ASTM).

It is available at: http://www.stockpreacher.com/n/STEM

StemCells Inc. (STEM) is a clinical-stage biotechnology company, focused on the research, development and commercialization of products derived from stem-cell technologies. It targets the development of cell-based therapeutics to treat diseases of the central nervous system and liver. The Company's lead product candidate, HuCNS-SC cells, are purified human neural stem cells, which can be expanded and banked until they are delivered as patient doses.

In the report, the analyst notes:

"STEM announced the publication of preclinical data demonstrating for the first time that transplantation of its purified human neural stem cells delays the loss of motor function in a mouse model of infantile NCL. ... In this research, these cells were transplanted in a mouse model of infantile NCL and compared to a control (non-transplanted) group. The results demonstrated that the transplanted cells engraft, migrate throughout the brain, and continuously secrete the missing lysosomal enzyme characteristic of NCL, which is needed to process cellular waste and keep neurons functioning and healthy. Compared with the control group, the mice that received the transplanted neural stem cells showed statistically significant reduction in cellular waste build-up, protection of critical host neurons and delayed loss of motor function.

"In December 2008, the FDA approved the Investigational New Drug Application to initiate a phase I clinical trial of HuCNS-SC cells in a second indication, Pelizaeus-Merzbacher Disease (PMD), a fatal myelination disorder in the brain. The Company is planning to initiate, in collaboration with the University of California, San Francisco (UCSF) Children's Hospital, a phase I clinical trial to evaluate the therapeutic potential of HuCNS-SC product candidate to treat PMD, by the end of 2009."

To read the entire report visit: http://www.stockpreacher.com/n/STEM

See what investors are saying about these stocks at: http://www.stockhideout.com/

StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.

CONTACT:  StockPreacher.com
          Jeff Bishop
          (469)-252-3505
          press@beaconequity.com